Bristol-Myers Squibb's put activity was labeled bullish. The report describes options trading, not a change in the company's business or plans, so its outlook is unchanged.
The reported bullish label reflects options activity, not a change in Bristol-Myers Squibb's medicines, sales, or plans. The story gives no company result to confirm that view, so it does not change the outlook for BMY.
Boston Scientific had a put trade labeled bullish. The report gives no new company result or plan, so this trading activity does not change its outlook.
Danaher's put trade was labeled bearish. The report describes options activity but gives no new company result or plan, so its outlook is unchanged.
Genmab's put activity was labeled bullish. The report gives no new company result or plan, so this trading activity does not change its outlook.
Iovance's call trade was labeled bearish. The report describes options activity but gives no new company result or plan, so its outlook is unchanged.
Eli Lilly's put trade was labeled neutral. The report gives no new company result or plan, so it does not change the company's outlook.
Follow Bristol-Myers Squibb Company (BMY) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for BMY